Overview
This study aims to explore the efficacy and safety of Pembrolizumab Combined With Double Platinum-Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer
Description
Inclusion criteria:
diagnosed with Non-small cell lung cancer EGFR and ALK and ROS1 negative Treatment naive Potentially Resectable identified by MDT
Eligibility
Inclusion Criteria:
- ≥18,Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
- Potentially Resectable NSCLC
- Treatment Plan is Crizotinb or Standard Chemotherapy
Exclusion Criteria:
- Patients with contraindication of chemotherapy
- Pregnant or breast feeding women